7501-44-2Relevant articles and documents
1,2-DIACYLGLYCEROL COMPOUND, PREPARATION METHOD THEREFOR, AND IMMUNOMODULATOR CONTAINING SAME AS ACTIVE INGREDIENT
-
Paragraph 0040, (2021/01/26)
Disclosed are a novel 1,2-diacylglycerol compound that useful for improving, preventing or treating inflammation-related diseases by inhibiting overexpression of various inflammatory cytokines such as IL-4 and IL-6 or chemokine CXCL8 related to the migrat
Bidirectional conversion between 3-monochloro-1,2-propanediol and glycidol in course of the procedure of DGF standard methods
Kaze, Naoki,Sato, Hirofumi,Yamamoto, Hiroshi,Watanabe, Yomi
experimental part, p. 1143 - 1151 (2011/11/12)
NMR observation revealed that bidirectional conversion occurred between 3-monochloropropane-1,2-diol (3-MCPD) and glycidol in the course of the analytical procedure of DFG standard method C-III 18 (09), option A; 3-MCPD was partly converted to glycidol at the transesterification step, and glycidol was converted partly to 3-MCPD at the derivatization step conducted at 80 °C under acidic condition in the presence of NaCl. Based on the proton numbers observed by 1H NMR, the degrees of the conversion were estimated to be 37 and >70%, respectively. In addition, epoxide ring-opening of glycidol and its esters was found to be ca. 90% by the acid treatment described in the method, option B. Thus, it was concluded that the standard method, option A, did not correctly give the combined amount of 3-MCPD esters and glycidyl esters in oils containing glycidyl esters, and the difference of the values obtained by options A and B did not correspond to the amount of glycidyl esters, either. In addition, derivatives of 3-MCPD with phenylboronic acid were not observed by NMR at the derivatization step, although they were detected by GC-MS in the organic phase at the following extraction step.
Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
-
Page/Page column 47, (2008/06/13)
The invention provides anti-apoptotic compositions lysophosphatidic acids and methods for making and using the compositions. Such compositions can also contain LPA potentiating agents, including proteins, lipid membrane structures and polymers such as polyethylene glycols. The compositions can additionally contain other pharmaceutically effective agents such as drugs, antibiotics, wound healing agents and antioxidants.